84 results about "Bcg bladder instillation" patented technology

The invention discloses a kit for detecting the mycobacterium tuberculosis infection and monitoring a clinical treatment effect. The kit provided by the invention comprises a specific antibody, namely an IP-10 antibody and / or CD14 antibody, an antigen irritant and a positive contrast irritant. The kit disclosed by the invention can be used for diagnosing an active tuberculosis patient or a tuberculosis latent infection patient and is not affected by BCG (bacillus calmette-guerin) inoculation. The sensitivity and the specificity of the kit for diagnosing the active tuberculosis patient are higher than those of a commercial T-SPOT.TB kit and can be up to 100 percent. After the antituberculosis therapy is performed for 1 month, the detection rates of over 80 percent of clinical tuberculosis patients are converted to be negative, so that the kit can be used for detecting the clinical antituberculosis treatment effect.

The invention relates to a low-temperature microorganism preservation protectant, as well as a preparation method and use thereof. The low-temperature microorganism preservation protectant is prepared from the following components: non-reducing saccharide, glycerin, a nonionic surfactant, a potassium salt, glutamate and water. The invention also discloses a technical method for preserving bacillus calmette-guerin at low temperature for long. A technical support is provided for deep development of related researches on the bacillus calmette-guerin.

The invention discloses a recombinant bacillus calmette-guerin vaccine secreting bacteria resuscitation somatomedin and application thereof. The recombinant bacillus calmette-guerin vaccine uses the bacillus calmette-guerin vaccine as host cell. An exogenous expression vector carrying out transfection on the host cell is an expression vector comprising a bacteria resuscitation somatomedin genetic fragment. The recombinant bacillus calmette-guerin vaccine can continuously secrete Rpf factors with bioactivity and can induce a humoral immunity response level and a cellular immune response level. An antibody which is generated by aiming at the exogenous Rpf can interdict the stimulating effect of the Rpf to MTB. The level of inducing IFN-gamma of the recombinant bacillus calmette-guerin vaccine is superior to that of BCG. The recombinant bacillus calmette-guerin vaccine is applied to preparation of a preventive immunity vaccine for MTB infection and / or MTB inapparent infection.

The invention provides a prediction method and prediction system of an irresponsive gamma globulin Kawasaki disease. The method comprises the following steps that 21 original parameters of SVM model building are collected; the modelling original parameters comprise gender, age, fever time during treatment, clinical classification, CRP detection value, WBC value, PLT value, Hb value, ALT value, AST value, ALB value, gamma globulin using time and clinical diagnosed symptom indicators; the clinical diagnosed symptom indicators comprise conjunctival injection, erythra, cracked lips, a strawberry-like tongue, lymphadenectasis of a neck, hard and swollen hands and feet, digit peeling, crissum peeling and a red and swollen bacillus calmette-guerin scar; discretization is conducted on the original parameters to obtain SVM characteristic values corresponding to the original parameters; the SVM characteristic values are regarded as base data, a SVM model is built, and through the SVM model, a complication with irresponsive gamma globulin of the Kawasaki disease is predicted. By means of the prediction method and prediction system, early intervening treatment can be conducted on a patient, recovery of damage to a coronary artery is promoted, and the prediction method and prediction system have important significance and value on diagnosis and treatment of the Kawasaki disease in the future.

The invention relates to the field of molecular immunology. In recent years, tuberculosis revives in the global range. The emergence of drug-resistant strain always invalidates antibiotic therapy and the normally used tuberculosis vaccine-BCG vaccine also has limitations. The invention aims at screening the molecular simulation peptide of epitope which can activate the protective immune response of human anti-mycobacterium tuberculosis, studying the protective immune response mechanism of the tuberculosis and further developing a novel concatenated poly epitope tuberculosis vaccine. The invention provides the molecular simulation peptide of the epitope which can activate the protective immune response of human anti-mycobacterium tuberculosis; the amino acid sequence of the peptide is shown as SEQ ID NO:14. The invention further provides a screening method and the function of the peptide. Therefore, the molecular simulation peptide of the invention can more effectively prevent and control the generation and the development of the tuberculosis.